Managing CAR T-Cell Toxicity: Impact of Steroid Prophylaxis on Toxicity and Outcomes

Demographic Characteristics, Incidence and Outcomes of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients Undergoing CAR T-Cell Therapy: An Analysis of the National Inpatient Sample (NIS) - 2021

Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: The Vanderbilt experience.

CAR T-cell therapy for solid tumours

Prophylactic Corticosteroids Allow Safe Outpatient Administration of Axicabtagene Ciloleucel with Comparable Toxicities to Other CAR-T Therapies in Large Cell Lymphoma

Acute Kidney Injury After the CAR-T Therapy Tisagenlecleucel

Chimeric Antigen Receptor T Cells: Toxicity and Management Considerations

Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel.

An Endothelial Activation and Stress Index (EASIX) Based Predictive Model for Neurotoxicity and Cytokine Release Syndrome (CRS) after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

Clonal Hematopoiesis Is Associated with Severe Cytokine Release Syndrome in Patients Treated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Association of Bridging Therapy Utilization with Clinical Outcomes in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Absolute Lymphocyte Count As a Predictor of Safety and Efficacy Post CART for Multiple Myeloma and B Cell Malignancies

Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma

Autoimmune Outcomes in Patients with Concurrent Autoimmune Disease Receiving CD19 CAR T-Cell Therapy for Lymphoma

7034 Background: Since its introduction into the world of oncology, chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed and refractory lymphomas. However, patients with HIV (PWH) have historically been excluded from CAR T-cell studies. This is likely due to assumed decreased efficacy and increased infection-related morbidity and mortality due to their immunocompromised status. This lack of understanding contributes to healthcare disparities, resulting in fewer individuals from this vulnerable population receiving this innovative treatment. Thus, this study aims to compare the 1-year survival and safety outcomes of CAR T-cell therapy for Hodgkin and Non-Hodgkin lymphomas in adult patients with and without HIV. Methods: Using TriNetX global health research network, we identified 35 PWH who received lymphoma-directed CAR T-cell therapy. For the control group, we identified 2,575 patients without HIV who received lymphoma-directed CAR T-cell therapy. We then conducted a log-rank test and calculated relative risks (RR) to compare outcomes in 1-year overall survival (OS) and incidence of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), bacteremia and sepsis. Results: In our group of PWH, we observed a mean age of 56.1+/-12.6 years at time of CAR T-cell therapy, compared to a mean age of 63.0+/-13.0 years in our group of patients without HIV. RR analysis demonstrated significantly increased 1-year risk for development of sepsis (RR=1.75, 95%CI 1.03, 2.97) and bacteremia (RR=2.41, 95%CI 1.41, 4.12) in our group of PWH. However, it showed no statistically significant differences in risk for development of CRS (RR=1.11, 95%CI 0.788, 1.57), ICANS (RR=1.23, 95%CI 0.723, 2.08), or death from any cause (RR=1.43, 95%CI 0.873, 2.35). Log rank test revealed no significant differences in 1-year OS (p=0.208) or incidence of CRS (p=0.567), ICANS (p=0.223), bacteremia (p=0.561) or sepsis (p=0.225). Median OS was not reached in either group. Conclusions: This data supports that PWH may be at increased risk of infectious complications, but not increased mortality, following lymphoma-directed CAR T-cell therapy. While this study is limited by a small cohort size, its results support the need to include PWH in future clinical trials to better understand the effect of HIV infection on CAR T-cell treatment outcomes.

Successful Development of an Outpatient Chimeric Antigen Receptor (CAR) T Cell Therapy Program